🟢 96/100

This product looks safe

  • Vitamin B3: 50mg is 1.4× the Tolerable Upper Intake Level (35mg)
  • 30% of ingredients have research evidence
C Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Vitamin B3: 50mg is 1.4× the Tolerable Upper Intake Level (35mg)

Label Data

11 Gram(s) Serving Size
40 Servings
Other Combinations Product Type
30% Evidence Coverage

Supplement Facts — Evidence Check

50 mg (250% DV)
⚠️ Exceeds Tolerable Upper Intake Level by 1.4× (UL: 35 mg) 📚 193 studies (Tier A: 5, B: 63)
RDA 14mg This product: 50mg UL 35mg
10 mg (500% DV)
📊 7.7× RDA — above typical dose (UL: 100 mg) 📚 113 studies (Tier A: 3, B: 35)
RDA 1.3mg This product: 10mg UL 100mg
12 mcg (200% DV)
📊 5.0× RDA — above typical dose 📚 138 studies (Tier A: 1, B: 44)
RDA 0.0024mg This product: 0.012mg
Sodium
56 mg (2% DV)
Potassium
80 mg
3500 mg
📊 Market median: 17.4mg (161 products)
Median 17.4mg This product: 3500mg
2000 mg
📊 Market median: 17.4mg (161 products)
Median 17.4mg This product: 2000mg
Valine
2000 mg
Amino Blend
1723 mg
Electrolyte & Mineral Blend
440 mg

Other Ingredients

Artificial Flavors Citric Acid Sucralose Sodium Chloride Malic Acid Beta-Carotene Red Beet powder

Label Claims — Verification

Structure/Function
All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

🧪 Formulation Notes

Lean muscle support formula

Support muscle growth Increased recovery Promote protein synthesis

The foundation of high performance nutrition

Additional Information

Nothing compares

Product Details

DSLD Entry Date 2021-03-25
Product Type Other Combinations
Form Powder
Brand 1st Phorm
DSLD ID 242705
Data Updated 2026-04-11

Research Evidence

241 Research Sources
55 Avg Quality Score
113 Meta Analysis
75 Systematic Review
32 Rct
11 Clinical Trial
3 Other
3 Regulatory Source
1 Cochrane Review
1 Narrative Review
1 Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016
View all evidence for Niacin →

Compare Similar Products

View all Niacin products →